An Analysis of the PALOMA-3 Trial

Nicholas Turner, PhD, consultant medical oncologist, The Royal Marsden Hospital, London, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Nicholas Turner, PhD, consultant medical oncologist, The Royal Marsden Hospital, London, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Clinical Pearls:

  • The PALOMA-3 trial is focusing on women who have progressed on their first-line hormonal therapy - There are a number of different options in this space, but fulvestrant is one of the strongest and has the best data when given under 500mg/dose
  • There is no evidence of any drug interaction between palbociclib and fulvestrant
  • Adding fulvestrant to palbociclib may improve the length of time that cancer can be controlled